NeuBase Therapeutics Inc (NBSE) has released an update.
NeuBase Therapeutics, Inc. is set to dissolve, liquidate its assets, and distribute them to shareholders after its Board of Directors deemed it the most beneficial route for maximizing stockholder value. The decision follows a thorough evaluation of various strategic options, including mergers and acquisitions. The dissolution plan is pending shareholder approval at an upcoming Special Meeting, the details of which will be announced alongside proxy materials to be filed with the SEC. However, the Board may still opt to abandon the liquidation if it’s no longer considered in the best interest of the stockholders.
For further insights into NBSE stock, check out TipRanks’ Stock Analysis page.
